Maastricht

• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 5 2022-07-20 Patients on treatment with Factor Xa Inhibitor needing for an urgent i
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR … Recruiting
  2024-512119-34-00 4 2022-06-20 MSI-H/dMMR metastatic colorectal cancer
• Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting
  2022-501893-21-00 4 2022-05-03 Acute myocardial infarction
• Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) Recruiting
  2023-506886-76-00 6 2022-03-23 ALK positive non-small cell lung cancer
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Recruiting
  2025-522883-34-00 6 2026-06-12 Metastatic cervical cancer
• Efficacy, Safety, and Tolerability of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Recruiting
  2025-522957-20-00 5 2026-05-29 Myotonic Dystrophy Type 1
• MetAddon: Methadone as co-analgesic for patients with metastatic bone pain: a double-blind randomized controlled trial Recruiting
  2025-522710-22-00 6 2026-05-28 Cancer, bone metastasis, pain
• PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f … Recruiting
  2023-506194-35-00 5 2026-05-22 Colorectal liver metastases
• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043) Recruiting
  2025-524160-38-00 5 2026-05-12 Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorect
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting
  2024-516993-31-00 5 2026-05-11 Renal Cell Carcinoma
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting
  2024-520014-22-00 5 2026-04-22 Locally advanced/metastatic urothelial carcinoma
• Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resec … Recruiting
  2024-516898-72-00 10 2026-04-17 Perihilar cholangiocarcinoma, distal cholangiocarcinoma
• A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy … Recruiting
  2025-523085-24-00 5 2026-04-13 Biliary Tract Cancer
• A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 Recruiting
  2025-521973-16-00 9 2026-03-31 Netherton Syndrome
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma
• Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait A … Recruiting
  2025-523692-39-00 5 2026-03-11 locally advanced rectal cancer
• The PEARL trial: Prevention of hepatic Encephalopathy by administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoi … Recruiting
  2024-512040-28-01 6 2026-03-01 Confirmed diagnosis of Alcoholic liver cirrhosis
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer

Showing 49–72 of 321 trials